News
-
-
PRESS RELEASE
Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Heidelberg Pharma AG announces amendment to royalty agreement with HealthCare Royalty and participation of Soleus Capital, securing financing until mid-2027. USD 20 million upfront from Soleus Capital and USD 25 million upon FDA approval of TLX250-Px -
-
PRESS RELEASE
EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Heidelberg Pharma AG announces amendment to royalty agreement with HealthCare Royalty and partnership with Soleus Capital, securing upfront and milestone payments -
-
-
-
-
-
PRESS RELEASE
Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
Heidelberg Pharma appoints Dr. Dongzhou Jeffery Liu as Chairman and CEO, replacing Prof. Andreas Pahl. The biotech company focuses on ADC technology for cancer treatment
